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Abstract
Up to now alpha 1-antitrypsin (AAT) augmentation therapy has been approved only for commercial use in selected
adults with severe AAT deficiency-related pulmonary emphysema (i.e. PI*ZZ genotypes as well as combinations of
Z, rare and null alleles expressing AAT serum concentrations <11 μmol/L). However, the compassionate use of
augmentation therapy in recent years has proven outstanding efficacy in small cohorts of patients suffering from
uncommon AAT deficiency-related diseases other than pulmonary emphysema, such as fibromyalgia, systemic
vasculitis, relapsing panniculitis and bronchial asthma. Moreover, a series of preclinical studies provide evidence of
the efficacy of AAT augmentation therapy in several infectious diseases, diabetes mellitus and organ transplant
rejection. These facts have generated an expanding number of medical applications and patents with claims for
other indications of AAT besides pulmonary emphysema. The aim of the present study is to compile and analyze
both clinical and histological features of the aforementioned published case studies and reports where AAT
augmentation therapy was used for conditions other than pulmonary emphysema. Particularly, our research refers
to ten case reports and two clinical trials on AAT augmentation therapy in patients with both AAT deficiency and,
at least, one of the following diseases: fibromyalgia, vasculitis, panniculitis and bronchial asthma. In all the cases,
AAT was successfully applied whereas previous maximal conventional therapies had failed. In conclusion, laboratory
studies in animals and humans as well as larger clinical trials should be, thus, performed in order to determine
both the strong clinical efficacy and security of AAT in the treatment of conditions other than pulmonary
emphysema.
Introduction
Alpha1-antitrypsin (AAT) deficiency is an autosomal,
codominant genetic disorder, characterized by the poly-
merization of abnormal, misfolded proteins in the rough
endoplasmic reticulum of hepatocytes and, secondarily,
a decreased concentration and activity of AAT in blood
and tissues. Although several degrees of AAT deficiency
are quite common worldwide, severe deficiency (i.e.
AAT serum levels below 11 μmol or 50 mg/dL) repre-
sents a rare condition affecting 1 per 2,000-5,000 Cauca-
sian individuals of Western European origin, with about
a quarter or half of them developing clinically significant
diseases [1,2].
Human alpha-1 antitrypsin (AAT), also called alpha-1
proteinase inhibitor (PI), and SERPINA1 (Serine Pro-
tease Inhibitor, clade A, member 1), is a 394-amino
acid, circulating glycoprotein with a molecular weigh of
52-kDa. AAT is medium sized and globular in shape
(6.7 × 3.2 nm), water soluble and diffusible into different
tissues, with an average of 4-5 day life span in circulat-
ing blood. AAT is mainly secreted by hepatocytes
(~80%) and, to a minor extent, by monocytes, pancreatic
islets, lung alveolar cells and colonic enterocytes, reach-
ing high mean concentrations in plasma (1-2 g/L).
Eighty percent of plasmatic protein diffuses into differ-
ent body tissues and approximately 10% reaches most
biological fluids [3].
Extensive data show that the major function of AAT is
the inhibition of over-expressed neutrophil elastase and
other serine proteinases (i.e. proteinase-3, myeloperoxi-
dase and cathepsin G from neutrophils, tryptase and
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physiological proteinase-antiproteinase balance [4-34].
Moreover, an increasing number of new inhibitory and
non-inhibitory properties conferring to ATT outstand-
ing anti-inflammatory, inmunomodulatory and antimi-
crobial attributes have been discovered in later years,
together with the fact that AAT activity is not only lim-
ited to lungs but also to most body tissues [35-38].
AAT gene has two alleles. Normal alleles are called M;
thus, normal individuals have genotype MM. The most
common severe deficiency allele is called Z (Glu342Lys);
in clinical practice over 95% of severely deficiency
patients have genotype ZZ (expressing 10-20% of serum
AAT). The remaining 5% belongs to patients with geno-
type SZ and about 30 rare deficiency and null pheno-
types, expressing 0-30% AAT serum levels. Most
common diseases related to severe AAT-deficiency are
pulmonary emphysema (found in around 3% of adults
with COPD), liver cirrhosis (2.5% of children and 10-
20% of PI*Z adult homozygotes), systemic vasculitis
(7%) and relapsing panniculitis (0.1%) [3,39,40].
In 1987 the Food and Drug Administration (FDA) pub-
lished the first guidelines on augmentation therapy with
intravenous infusions of purified AAT obtained from
human serum of adults suffering from moderate pulmon-
ary emphysema (FEV1 30-65%) and severe AAT deficiency
(i.e. PI*ZZ genotypes and combinations of Z, rare and null
alleles expressing AAT serum concentrations < 11 μmol
or 50 mg/dL) [41]. Taking into account scientific evidence
and knowledge, the American Thoracic Society, the Eur-
opean Respiratory Society, the American College of Chest
Physicians and the American Association for Respiratory
Care recommend augmentation therapy for selected
patients with lung emphysema. Augmentation therapy not
only has been approved in the US but also in Germany,
Canada, Italy, Spain, Austria, Ukraine, Argentina and Bra-
zil, with similar criteria of use [3,42-52].
In the last years, preclinical studies in cells, animal
models and small cohorts of humans provided initial evi-
dence for the efficacy of AAT in several infectious dis-
eases, diabetes mellitus, organ transplant rejection and
other possible inflammatory diseases [38,53-60]. As a
consequence, the number of medical applications and
patents for other indications of AAT other than pulmon-
ary emphysema is increasing http://www.omnibio-
pharma.com/development. In this context, clinical
observations describing the remarkable (even impressive)
efficacy of the augmentation therapy in AAT deficiency
patients with fibromyalgia, systemic vasculitis, panniculi-
tis and bronchial asthma have also been reported [61-70].
According to Jenicek’s statement on clinical case report-
ing, these observations should be taken into account:
“Although a case report has the weakest level of Evidence
Based Medicine, sometimes an unusual case may become
an “index case”, and it may lead to the formulation of
new hypothesis on diagnostic and therapeutic options”
[71]. The aim of the present manuscript is to compile
published case reports and small trials where augmenta-
tion therapy was provided, on a compassionate basis, to
humans with disorders other than pulmonary emphy-
sema and to discuss their results in the light of current
knowledge on AAT deficiency-related disorders.
Methods
Firstly, a research on the MEDLINE database (1966-
2010) was made using the generic terms: “alpha-1 anti-
trypsin”, “alpha-1-proteinase inhibitor” and “alpha-1
antitrypsin deficiency” and combining them with one of
t h ef o l l o w i n gk e yc o n c e p t s :“augmentation therapy”,
“replacement therapy”, “treatment”.A f t e r w a r d s ,am o r e
specific search was carried out adding to the previous
terms one of the following terms: “infectious diseases”,
“inflammatory diseases”, “associated diseases”,( " N O T
emphysema”), “fibromyalgia”, “human immunodeficiency
virus”, “HIV”, panniculitis”, “vasculitis”, “bronchial
asthma”, “graft rejection”, “diabetes”, “influenza”, “tuber-
culosis” and “anthrax”. We also consulted EMBASE
Excerpta Medica, SciVerse Scopus and the Cochrane
Library databases in order to search for abstracts of
similar types of papers, as well as bibliographic refer-
ences of previously retrieved articles, authors’ databases
and reviews from several experts on this topic.
Only reports related to human beings were selected.
Studies on augmentation therapy for pulmonary emphy-
sema have not been included in the present analysis,
considering this topic to be out of the scope of the pre-
sent manuscript.
Results
Ten case reports [61-68] and two clinical trials [69,70]
have been found on intravenous AAT augmentation
therapy in 12 patients with both AAT deficiency and
one of the following diseases: vasculitis, panniculitis,
fibromyalgia and bronchial asthma. Ten of these 12
treated patients had genotype PI*ZZ [61-68] and the
remaining 2, PI*MZ.[69,70].
1. Vasculitis
In 1995 Dowd et al (University of Louisville School of
Medicine, Louisville, Kentucky) reported a case of to “a
49-year-old man, with a PI*ZZ genotype and AAT
serum of 24 mg/d, suffering from extensive cutaneous
leukocytoclastic vasculitis, with multiple recurrences
partially controlled with colchicine, prednisone, plasma
infusions and plasma-exchange therapy” [61]. Authors
describe the occurrence of repetitive outbreaks of fever,
chills, purpuric papules and nodules in lower extremi-
t i e s ,a r m s ,f a c e ,t r u n k ,h a n ds and the lateral abdominal
Blanco et al. Orphanet Journal of Rare Diseases 2011, 6:14
http://www.ojrd.com/content/6/1/14
Page 2 of 11wall, provoking large vitiligo areas in elbows, knees, dor-
sal hand and pretibial surfaces. A biopsy skin sample
showed alterations related to leukocytoclastic vasculitis
(i.e. inflammatory involvement of medium and small
vessels, red blood cell extravasations, edema and clear
neutrophilic invasion with leukocytoclasia (disrupted
neutrophils). The results of a complete blood cell count,
serum multiphasic analysis and urinalysis were normal.
Studies with normal or negative findings included assays
for antinuclear antibody, antibodies to extractable
nuclear antigen, antinuclear DNA, complement levels
and hepatitis B surface antigen. The chest roentgen-
ogram was within normal limits as well as pulmonary
function tests. Five years later, the patient displayed a
“dramatic response after 1 dose of Prolastin
® (60/mg/
Kg), with improvement <6 hrs, and total resolution <48
hrs” and “good control with long-term augmentation
therapy (60/mg/Kg)/1-2 weeks” (Figure 1).
2. Panniculitis
From 1987 to 2010 seven cases of AAT deficiency-
related refractory relapsing panniculitis, treated with
AAT as the last resource, were published [62-67]. The
two first cases were reported by clinicians in the Mayo
Clinic, Rochester, Minn, in 1987 [62]. Ten years later, 2
other cases were reported by the Northwestern Univer-
sity Medical School of Chicago [63,64], and, from 2002,
3 new cases (1 each from the UK [65], Norway [66] and
Germany [67]) were reported by several European
authors. All these 7 patients were females with geno-
types PI*ZZ. Their mean AAT serum concentrations
were 29 mg/dL (range: 20-46), and their mean age 44
years (range: 21-65). In all the cases sequential infusions
of AAT were applied after the repetitive failure of con-
ventional therapies [i.e. antibiotics (doxycycline, minocy-
cline, cloxacillin and nafcilina), dapsone, systemic
corticosteroids, ciclofosfamida, chloroquine, nitrogen
mustard, plasma infusions, plasmapheresis, etceteras].
As a whole, skin samples showed a high expression of
cell components, being neutrophil invasion the most
relevant finding. They also disclosed the variable pre-
sence of scattered monocytes, lymphocytes and macro-
phages, areas of tissue destruction, fibroblasts and
fibrosis, inflammation and rupture of fibrous septa
Abrupt development of nodules and erythematous and purpuric papules in lower extremities, arms,
elbows, trunk, thigh and lateral abdominal wall; metacarpophalangeal joint inflammation and
episodes of fever, chills and malaise.
Skin biopsy of purpuric lesions: Leukocytoclastic Vasculitis.
Alpha-1-antitrypsin Deficiency (AAT serum levels 24 mg/d, phenotype PiZZ).
Treatment with colchicine 0.6 mg twice/day and oral prednisone 40 mg/day.
Multiple recurrences of cutaneous vasculitis, partially controlled with Prednisone.
Augmentation therapy withAAT: 60 mg/kg body weight (total: 5.5 grams).
No other concurrent therapy was used.
After the first infusion, lesions improved significantly within 2-6 hours and totally resolved within
48 hours.
The patient was clear of lesions for approximately 10 days before a new eruption reappeared.
Relapse was again controlled withAAT.
The patient continues to receive Prolastin (5.5 grams every 1-2 weeks), successfully
controlling vasculitis.
Clinical Events/ Diagnosis/ Treatment 
1987
(49)
1988
(50)
1993
(55)
1995
(57)
Year 
(Age)
Figure 1 Timeline of clinical events in a case of leukocytoclastic vasculitis related to ZZ alpha-1-antitrypsin deficiency.A A T :a l p h a - 1 -
antitrypsin.
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down, scars, fistulas and ulcers. In the only case where
Z polymers were investigated, they were demonstrated
to appear both in active lesions and surrounding non-
inflamed tissues [67]. The response to AAT infusions
was uniformly positive in all the cases, being described
in some reports as “dramatic”, “very-high and rapid”,
“life-saving”, etc. (Figure 2).
In the same context, the results of two liver trans-
plants in PI*ZZ patients with end-stage liver cirrhosis
Author, Year
[reference] 
Source
Sex (years)
Genotipe
(AAT serum in
mg/dL)  
Clinical data Effect of augmentation therapy
Smith et al, 
1987 [62]
Rochester, US
Case 1. 
F (65).  
ZZ (40)  
Extensive ulcerative  relapsing 
panniculitis requiring
hospitalization
After the failure of Indomethacin, Prednisone, 
Azathioprine, Ketoconazole and Dapsone, a single 
infusion of AAT (60 mg/Kg/week) was applied in 2
severe recurrences, with significant clinical 
efficacy.   
Smith et al, 
1987 [62]
Rochester, US
Case 2. 
F (36). 
ZZ (20)  
Extensive ulcerative relapsing 
panniculitis requiring 
hospitalization    
After the failure of Prednisone and Dapsone, 7
weekly infusions of AAT were successfully applied
together with Dapsone and Prednisone.  
Furey et al. 
1996 [63]
Chicago, US. 
Case 3. 
F (62). 
ZZ. (24)  
Extensive ulcerative relapsing 
panniculitis with massive edema 
(in legs, thighs and abdomen)
requiring hospitalization   
A single infusion of AAT (60 mg/ Kg) was
provided. The response was dramatic. Within 24 
hours, the patient could walk; and after 3 weekly 
infusions, both massive edema and panniculitis 
were resolved. 
O'Riordan et al, 
1997 [64]
Chicago, US
Case 4. 
F (62). 
ZZ (23)  
Severe ulcerative relapsing 
panniculitis
Panniculitis was completely resolved with 3 weekly 
doses of IV AAT (60/mg/Kg). Skin lesions recurred 
6 months later but were resolved with 2 additional
infusions, once levels of AAT were over 50 mg/dL. 
Chowdhury et 
al 2002 [65]
Cardiff, UK. 
Case 5. 
F (33). 
ZZ (46) 
Rapidly progressive panniculitis, 
septic shock and multiple life-
threatening complications
Augmentation therapy was life-saving. Prolastin® 
quickly reduced inflammation within 24 hours.
Since then, the patient has been feeling well, 
inflammation-free, under a treatment of 6 g/ week
of Prolastin®. 
Kjus T et al, 
2003 [66].  
Oslo, Norway
Case 6. 
F (21). 
ZZ (30) 
Ulcerated chronic relapsing
panniculitis. 
After the failure of dapsone and doxycycline, the 
patient was successfully treated with i.v. infusions 
of Prolastin® (60/mg/Kg) once a week. “All 
lessons resolved within 2 days; reappeared after 4
weeks, and again disappeared 1-2 days after 
Prolastin®. At present, well controlled with 
infusions every 4th week”
Gross B [67]. 
2009. 
Frankfurt, 
Germany.
Case 7.
F (31). 
ZZ (22) 
Ulcerated relapsing panniculitis.  
 Z-type AAT polymers were found 
in skin, supporting the hypothesis 
of the pro-inflammatory role of 
polymers. 
The long-term use of intravenous AAT
augmentation therapy (Prolastin®) during 3 years 
reduced both the frequency and severity of 
panniculitis. 
Figure 2 Demographic and clinical data of 7 patients with relapsing panniculitis associated to ZZ alpha-1-antitrypsin deficiency
treated with alpha-1-antitrypsin augmentation therapy. F: female. AAT: alpha-1-antitrypsin.
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ized. In both cases, a rapid and steady control of panni-
culitis was observed after the replacement of each
damaged liver by a new efficient organ, restoring AAT
serum levels back to normal. The first case was reported
in 1997 by O’Riordan et al. (Northwestern University
Medical School, Chicago, IL, USA) [64]. Authors
observed evolution in “a 53-year old man...ZZ (AAT: 17
mg/100 ml)...with end-stage liver cirrhosis and relapsing
panniculitis... [who] received a liver transplant. His new
phenotype was PI*MM... and serum AAT of 153 mg/dL.
O n em o n t ha f t e r . . . ac o m p l e t er e s o l u t i o no ft h es k i n
lesions” was noticed.
The second case was reported by Fernandez-Torre et
al. from the Hospital Juan Canalejo, La Coruña, Spain,
in 2009 [72]. On the contrary, authors noticed altera-
tions in “A 56-year-old MM patient [who] acquired a
ZZ phenotype after a liver transplant for alcoholic liver
cirrhosis. Subsequently, he developed cirrhosis and pan-
niculitis. Liver transplantation was again performed,
with complete resolution of the skin lesions and restora-
tion of AAT serum levels (from 28 to 270 mg/dl)...11
months later he remains asymptomatic”.
I nt h es a m ec o n t e x t ,d eO l i v e i r ae ta l .( S ã oP a u l o ,
Brazil) published in 2004 the case of a 23-year-old
patient with extensive, ulcerative relapsing panniculi-
tis, and AAT serum levels of 22 mg/dL and pheno-
type ZZ [73]. The patient was treated with 16
sessions of plasma exchange therapy, with cutaneous
lesions clinically controlled after five sessions. AAT
increased to 60 mg/dL after the first session, slowly
decreasing to initial levels in approximately 15 days
until the next plasma infusion (when AAT levels
increased again and, thus, relapses were promptly
controlled). This case shows many similarities with
the first report on the use of plasma exchange therapy
in panniculitis, made in 1986 by Viraben et al. [74],
who used fresh plasma every other day for 2 weeks,
with dramatic effectiveness. Both authors consider
plasma exchange as an effective therapeutic alterna-
tive for unresponsive patients to conventional treat-
ments, thus highlighting the necessity of further
studies with a larger number of individuals.
3. Fibromyalgia
Up to date three cases have been reported by Blanco et
al. (Hospital Valle del Nalón, Principality of Asturias,
Spain) [68,69].
Cases 1 and 2 were reported in 2004 [68]. In the early
nineties two PI*ZZ Spanish sisters with severe fibro-
myalgia started AAT replacement therapy. During the
next 3 and 5 years, respectively, they both experienced a
rapid, progressive and constant control of fibromyalgia
symptoms. However, a commercial shortage of AAT by
1998 led to the annual interruption of infusions for 4-6
consecutive months during 5 years. As a result, fibro-
myalgia symptoms recurred during infusion interruption
and disappeared completely whenever infusions were
resumed. Currently, both patients are regularly treated
with Prolastin
®, and do not have fibromyalgia symptoms
anymore (Figure 3).
Case 3 was reported in 2010 [69]. In 2004 a patient
with both AAT deficiency (MZ) and severe fibromyal-
gia/CFS (Chronic Fatigue Syndrome) participated in a
trial with AAT-intravenous augmentation therapy after
the failure of conventional therapies. Since then, the
patient has experienced a very good clinical response
(Figure 4).
At present, the 3 patients continue to be under long-
term AAT augmentation therapy with successful results.
4. Bronchial asthma
In 2008, Blanco I, et al. (Hospital Valle del Nalón,
Asturias, Spain) reported the case of a Caucasian 27-
year old woman, working as a cleaner, who started to
suffer from recurrent dyspnoea, wheezing, cough and
chest tightness [70]. A totally reversible and variable
spirometric airflow limitation was evidenced, and she
was diagnosed with bronchial asthma (Figure 5). In the
following years, she was also diagnosed with nasal
polyps as well as Aspirin-Sensitive Asthma (ASA). Iso-
electric-focusing and nephelometry showed that the
patient had a deficient phenotype MZ with intermediate
low AAT serum concentrations. On the other hand,
PCR genotyping sequenced exons II-V of the AAT gene,
diagnosing a genotype M3Z. The results of several stu-
dies to rule out other conditions, mimicking or worsen-
ing bronchial asthma, were either normal or negative
except for immune hyperthyroidism. The patient was
firstly treated with Carbimazole and later with radioiso-
tope therapy (causing iatrogenic hypothyroidism but
easily managed with Levothyroxine). However, asthma
persisted with frequent at night symptoms, daily attacks
of dyspnoea and limited physical exertion. As pulmonary
function significantly worsened due to asthma attacks,
the patient had to use frequently the emergency medical
services and even was admitted to hospital in several
occasions. She was prescribed long-term prednisone
tablets (15-30 mg/day). However, asthma continued to
be out of control and bronchial obstruction, permanent.
Moreover, significant side effects of glucocorticoid drugs
appeared in the following months. As a consequence,
the patient experienced severe limitation of her physical
capacity which negatively affected her mental state and
social and personal life. The results of a computerized
axial tomography of the chest to rule out pulmonary
emphysema and other intercurrent complications were
within normal limits. Due to the unfavourable clinical
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with AAT augmentation therapy (60 mg/Kg/week dose
for the first two weeks and 120 mg/biweekly for 7
months). As the results of the trial were significantly
favourable, the treatment continued. The continuous
administration of AAT infusions stopped the decline in
lung function. In 1991-1994 (period 1) her FEV1
(expressed by mean and standard deviation) was equiva-
lent to 69% (17); in 1995-2003 (period 2) it declined to
43% (5.14); and from 2004, once the AAT augmentation
t h e r a p ys t a r t e d ,t o2 0 0 7( p e r i o d3 ) ,i tr o s eu pt o5 2 %
(3.75). Statistical significance was found between period
1 and period 2 (p = 0.000), period 1 and period 3 (p =
0.000), and period 2 and period 3 (p = 0.001). As
expected, the augmentation therapy increased the AAT
serum levels of the patient, measured by nephelometry
and expressed in mg/dL, from basal values of 0.78 (0.04)
to 1.08 (0.10) pre-infusions and 2.61 (0.34) post-infu-
sions. Moreover, AAT augmentation therapy signifi-
cantly reduced the number of emergency visits
and hospital admissions (22 emergency visits in 2001-
2003 vs. 8 in 2004-2007; and 4 hospital admissions in
P= 0.00
P= 0.00
P= 0.00
Figure 4 Effects of a 6-month trial with alpha-1-antitrypsin
augmentation therapy and placebo in a Fibromyalgia and
Chronic Fatigue Syndrome patient with intermediate MZ
alpha-1-antitrypsin deficiency. FIQ: Fibromyalgia Impact
Questionnaire. HAQ: Health Assessment Questionnaire.
Worldwide Prolastin® shortage
Periodic interruption of infusions
4-6 months per year
Clinical observations
Clinical events
Gradually, total control of FM-related symptoms
after 2-3 infusions
Start of Prolastin® infusions
Diagnosis: FM
(44 ys)
Patient 1
(year of birth)
Diagnosis: ZZ 
(38 ys)
1995
1951
Patient 2
(year of birth)
Diagnosis: ZZ 
(34 ys)
Diagnosis: FM
(39 ys)
2003
2010
1998
Good control of FM symptoms with Prolastin® infusions since the end 
of 1998-2003 shortage period
2003
1998
1993
1947
1985
2010
Gradual recurrence of 
FM symptoms when 
infusions were halted
Gradual control of 
FM symptoms 
when infusions 
were resumed
Figure 3 Effects of augmentation therapy in 2 ZZ Alpha-1-antitrypsin deficiency sisters with fibromyalgia (FM).
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was also reduced shortly after the beginning of the aug-
mentation therapy, facilitating the elimination of chronic
corticoid side effects and progressively reducing the
high score of Asthma Quality of Life (AQL) in 2003
from 10 to 3 points in 2007 (Figure 6).
Conclusions
AAT deficiency is a congenital disorder with a remark-
able variability in its clinical presentation [3]: some sub-
jects can develop liver cirrhosis and others pulmonary
emphysema; to a minor extent, they can also develop
panniculitis, vasculitis, bronchial asthma or fibromyalgia;
and more than one third of the remaining carriers can
stay symptomless their entire life.
The 12 subjects mentioned in the present paper suf-
fered from less common AAT deficiency-related diseases
(i.e. leukocitoclastic vasculitis; relapsing panniculitis,
fibromyalgia, and refractory asthma). All these patients
have in common AAT deficiency genotypes (10 ZZ, 2
MZ). Also they all experienced a positive response to
intravenous AAT augmentation therapy, applied on a
compassionate basis as the last resource after the repeti-
tive failure of conventional therapies and the extremely
difficult clinical control of AAT deficiency-related dis-
eases (life-threatening in some cases).
The skin samples of the patient with leukocytoclastic
vasculitis related to ZZ AAT deficiency showed acute
and chronic inflammation. Neither anti-neutrophil cyto-
plasmic antibodies (ANCA) nor anti-neutrophil enzyme
proteinase 3 (PR3-ANCA) antibodies were analyzed.
Although the pathophysiological mechanisms of vasculi-
tis have not been determined yet, they seem to be
related to inflammatory mechanisms mediated by neu-
trophil invasion of the small and medium vessels. The
excess of proteinase-3, not neutralized by AAT, could
also play an important role in AAT deficiency subjects
with antineutrophilic cytoplasmatic antibody C-ANCA
Figure 5 Chronology of clinical events in an MZ-AAT patient with severe persistent asthma. AAT: Alpha1-antitrypsin. FEV1: Forced
Expiratory Volume in 1 second.
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PR3, the PR3-AAT imbalance in AAT deficiency-related
vasculitis could lead to increased circulating levels of
PR3 and trigger the synthesis of PR3-ANCA antibodies
[39]. AAT deficiency-related vasculitis would be, there-
fore, restricted to PR3-ANCA-positive cases and not to
less common occurrences of MPO-positive or ANCA-
negative cases. On the other hand, patients with both
vasculitis and AAT deficiency have been reported to
have a reduced ability to bind PR3 released by neutro-
phils previously activated, thus promoting PR3-mediated
proteolytic vessel damage. Actually, several findings
show that the disease course of Wegener’s granulomato-
sis (WG) is more severe when it is related to AAT defi-
ciency than when it is not. This supports the hypothesis
that AAT deficiency could trigger vasculitis by means of
PR3-ANCA autoimmunity [40]. The role of circulating
Z polymers, attacking the endothelial walls of blood ves-
sels and promoting vasculitic responses, has not been
determined yet nor whether all patients with manifesta-
tions of vasculitis and severe AAT deficiency could ben-
efit from AAT augmentation therapy. However, the
administration of this glycoprotein seems to be logical
for selected cases of AAT deficiency-related refractory
vasculitis.
The pathophysiological mechanisms of panniculitis in
AAT deficiency subjects have not been determined yet.
As some hypotheses suggest an inflammatory process
mediated by neutrophils invading the subcutaneous fat
layer, the most logical mechanism seems to be the
unopposed anti-inflammatory proteolytic damage by
neutrophil-serine proteinases in the context of defi-
cient serum levels of AAT [39]. In one of the afore-
mentioned cases of the present study, Z polymers were
found in both active lesions and surrounding non-
inflamed tissues, suggesting a potential pro-inflamma-
tory role of polymers in the development of panniculi-
tis. The histological features of panniculitis, especially
neutrophil invasion, could explain the rapid clinical
resolution of inflammation with AAT augmentation
therapy. Therefore, its application should be tried in
cases which fail to respond to conventional therapeutic
approaches.
Fibromyalgia syndrome is characterized by the central
amplification of sensory impulses (central sensitization)
causing autonomic, hormonal, immune and cytokine
interactions and perturbations. Fibromyalgia can result
from the disordered expression of inflammatory sub-
stances, amplified by genetic factors. Recent evidence
indicates that fibromyalgia can be added to the list of
AAT deficiency-related diseases. Main evidence ele-
ments include: (I) The short and long-term repetitive
positive response to AAT augmentation therapy showed
by the three aforementioned patients with both AAT
deficiency and fibromyalgia [68,69]. (II) An epidemiolo-
gical study showing a twofold higher frequency of PI*Z
allele in fibromyalgia patients than in general population
(4% vs. 2%), with a calculated prevalence of MZ, SZ and
ZZ deficiency genotypes being 2-4 times higher in fibro-
myalgia patients than in general population [75]. There-
fore, AAT deficiency should be considered as a
predisposing factor for the development of early and
severe onset of fibromyalgia in a subgroup of patients
with AAT serum levels lower than normal (7% MZ,
0.5% SZ and 0.2% ZZ). (III) A case-control study show-
ing plasma levels of MCP-1, VEGF and TNF-alpha sig-
nificantly lower in AAT deficiency subjects with
fibromyalgia than in controls [76]. (IV) A blinded inmu-
nohistochemical study of skin biopsies performed in 112
subjects (63 fibromyalgia vs. 49 controls) with AAT nor-
mal and deficient genotypes. The results showed a sig-
nificantly increased number of mast cells in the dermis
of fibromyalgia patients, with a proportion fibromyalgia/
controls of about 5:1 cells per microscopic high power
field (p = 0.000) [77]. Mastocytes positively stained with
t r y p t a s e ,A A Ta n dP A R - 2a n t i b o d i e sa sw e l la sw i t ha
C C
Figure 6 Effects of long-term augmentation therapy with
alpha-1 antitrypsin in an MZ-AAT severe persistent asthma.
Forced Expiratory Volume (A), Alpha-1-antitrypsin (AAT) serum
concentrations (B), and Asthma Quality of Life (C) scores after and
before alpha-1-antitrypsin infusions.
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Page 8 of 11kit receptor marker (CD117) and a cell activation mar-
ker (CD63), showing that about 50-80% of these masto-
cytes were activated. Remarkably, the skin samples of
the 3 patients under long-term AAT augmentation ther-
apy did not show any clinical fibromyalgia manifesta-
tions but also an increased number of dermal mast cells.
Therefore, exogenous AAT could serve as a mast cell
stabiliser and, as demonstrated in some laboratory stu-
dies, as a neutraliser of certain mast cells mediators (i.e.
histamine and serine proteinases, such as tryptase and
chymase) [17-19]. AAT augmentation therapy should be
considered to treat selected cases of AAT deficiency-
related refractory fibromyalgia not responding to con-
ventional therapeutic measures, and larger trials are
needed to determine the strong clinical efficacy of AAT
in fibromyalgia patients.
Histological samples from airways were not collected in
the case of the patient with bronchial asthma. However, it
is worth noting that severe asthma is considered as an
inflammatory airway disease related to sub-acute and
chronic inflammation maintained by eosinophils, masto-
cytes, dendritic, epithelial and endothelial cells, baso-
philes, T lymphocytes, macrophages and neutrophils.
Therefore, AAT could also play a determining anti-
inflammatory role in counteracting the effects of released
oxidants, cytokines, proteinases and other inflammation
mediators. Precisely, the imbalance between elastase and
AAT in asthmatic subjects has been already described as
well as the relation of airway inflammation to abnormal
high levels of active elastase, detected in patients’ samples
of induced sputum [78]. Neutrophil elastase has not only
proteolytic properties but also acts as a powerful secreta-
gogue. Particularly, recent evidence indicates the persis-
tence of neutrophilic and eosinophilic inflammation in
patients’ airways with severe asthma, and the activation
by neutrophil proteinases (i.e. elastase, cathepsin G and
proteinase-3) of peripheral blood leukocytes in order to
p r o d u c es u p e r o x i d ea n dp r o i nflammatory cytokines,
which can further aggravate airway inflammation [79].
On the other hand, it is worth mentioning that the airway
smooth muscle (ASM) not only has contractile properties
but also is involved in the pathogenesis of asthma, produ-
cing inflammatory mediators. Human neutrophil elastase
is a mitogen which activates ASM cells through extracel-
lular signal-regulated kinase (ERK) signaling pathway
[80]. Other interesting study shows that the allergic sti-
mulation of airways provokes the release of elastase, tis-
sue kallikrein (TK) and reactive oxygen species (ROS),
reducing AAT activity and contributing to airway hyper-
reactivity (AHR) [81]. Moreover, the bronchoconstriction
caused by elastase, high-molecular-weight kininogen and
ROS and AHR induced by both ROS and antigen was
stopped thanks to the application of 10 mg of recombi-
nant AAT, suggesting the key role of AAT in regulating
airway responsiveness [82]. In conclusion, the positive
effects of AAT augmentation therapy observed in this
case support the hypothesis of a proteinase-antiprotei-
nase imbalance in the pathogenesis of asthma, reaffirm-
ing the need for further studies on the mechanisms of
this bronchial disease and the efficacy of AAT augmenta-
tion therapy in selected AAT deficiency subjects with
refractory asthma.
In summary, all these 12 cases should promote further
laboratory studies in animals and humans as well as lar-
ger clinical trials in order to determine the strong effi-
cacy of AAT augmentation therapy in diseases other
than pulmonary emphysema, especially as a powerful
anti-inflammatory agent in processes such as fibromyal-
gia, vasculitis, panniculitis and bronchial asthma.
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